Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer.

British journal of cancer - 1 Nov 2024

Gu Yun, Sun Mengyao, Fang Hanji, Shao Fei, Lin Chao, Liu Hao, Li He, He Hongyong, Li Ruochen, Wang Jieti, Zhang Heng, Xu Jiejie

Abstract excerpt

BACKGROUND: This study aimed to reveal the effect of TP53 status on clinical outcomes and underlying mechanism in gastric cancer (GC) patients. METHODS: TP53 status was divided into three groups according to genome sequencing, namely clonal mutations with LOH (C-LOH), clonal diploid or subclonal mutations (CD-SC), and wild type (WT). The p53 protein activity was divided into over-expression (OE), Null and WT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Immunotherapy

Share to Loss of Heterozygosity

Share to Mutation

Share to Stomach Neoplasms

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 39217196
DOI: 10.1038/s41416-024-02825-1
PMCID: PMC11473753

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer.PMID 39217196Read ↗

Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric CancerSemantic proximity Read ↗

Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer.Semantic proximity Read ↗

Differential genetic mutations and immune cell infiltration in high- and low-risk STAD: Implications for prognosis and immunotherapy efficacy.Semantic proximity Read ↗

Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.Semantic proximity Read ↗

Landscape of somatic mutations in gastric cancer assessed using next‑generation sequencing analysisSemantic proximity Read ↗

Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status.Semantic proximity Read ↗

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancerSemantic proximity Read ↗

Redefining aberrant P53 expression of gastric cancer and its distinct clinical significance among molecular-histologic subtypes.Semantic proximity Read ↗

The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations.Semantic proximity Read ↗

Non-CpG sites preference in G:C > A:T transition of TP53 in gastric cancer of Eastern Europe (Poland, Romania and Hungary) compared to East Asian countries (China and Japan)Semantic proximity Read ↗

TP53 R273C Mutation Is Associated With Poor Prognosis in LGG PatientsSemantic proximity Read ↗

PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.